Inhaled granulocyte-macrophage colony stimulating factor for first pulmonary recurrence of osteosarcoma: Effects on disease-free survival and immunomodulation. A report from the Children's Oncology Group

Clinical Cancer Research

Volumn 16, Issue 15, 2010, Pages 4024-4030

  Arndt, Carola A S ^a   Koshkina, Nadya V ^b   Inwards, Carrie Y ^a   Hawkins, Douglas S ^c   Krailo, Mark D ^d   Villaluna, Doojduen ^e   Anderson, Peter M ^b   Goorin, Allen M ^f   Blakely, Martin L ^g   Bernstein, Mark ^h   Bell, Sharon A ^a   Ray, Kaylee ⁱ   Grendahl, Darryl C ^a   Marina, Neyssa ^j   Kleinerman, Eugenie S ^b  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c SEATTLE CHILDREN S HOSPITAL   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e CHILDREN S ONCOLOGY GROUP   (United States)

^f DANA FARBER CANCER INSTITUTE   (United States)

^g UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^h IWK HEALTH CENTRE   (Canada)

ⁱ OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^j STANFORD UNIVERSITY MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CLUSTERIN; FAS ANTIGEN; FAS LIGAND; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; PROTEIN S 100; T6 ANTIGEN;

ADOLESCENT; ADULT; ARTICLE; BRONCHOSPASM; CANCER GROWTH; CANCER RECURRENCE; CHILD; CHILD CARE; CLINICAL ARTICLE; COUGHING; DOSE RESPONSE; DRUG DOSE ESCALATION; DYSPNEA; EVENT FREE SURVIVAL; FEASIBILITY STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; LUNG CANCER; LUNG TOXICITY; MALE; MULTIPLE CYCLE TREATMENT; OSTEOSARCOMA; PRIORITY JOURNAL; SCHOOL CHILD; TREATMENT OUTCOME; WHEEZING;

ADMINISTRATION, INHALATION; ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; CHILD; DISEASE-FREE SURVIVAL; FEASIBILITY STUDIES; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNOMODULATION; KAPLAN-MEIERS ESTIMATE; LUNG NEOPLASMS; MALE; OSTEOSARCOMA; YOUNG ADULT;

EID: 77955122716     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-0662     Document Type: Article

References (30)

1. Chou AJ, Merola PR, Wexler LH, et al. Treatment of osteosarcoma at first recurrence after contemporary therapy: the Memorial Sloan-Kettering Cancer Center experience. Cancer 2005;104:2214-21.
2. Duffaud F, Digue L, Mercier C, et al. Recurrences following primary osteosarcoma in adolescents and adults previously treated with chemotherapy. Eur J Cancer 2003;39:2050-7.
3. Ferrari S, Briccoli A, Mercuri M, et al. Postrelapse survival in osteosarcoma of the extremities: prognostic factors for long-term survival. J Clin Oncol 2003;21:710-5. (Pubitemid 46621907)
4. Hawkins DS, Arndt CA. Pattern of disease recurrence and prognostic factors in patients with osteosarcoma treated with contemporary chemotherapy. Cancer 2003;98:2447-56.
5. Kempf-Bielack B, Bielack SS, Jurgens H, et al. Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS). J Clin Oncol 2005;23:559-68.
6. Pastorino U, Valente M, Gasparini M, et al. Median sternotomy and multiple lung resections for metastatic sarcomas. Eur J Cardiothorac Surg 1990;4:477-81.
7. Saeter G, Hoie J, Stenwig AE, Johansson AK, Hannisdal E, Solheim OP. Systemic relapse of patients with osteogenic sarcoma. Prognostic factors for long term survival. Cancer 1995;75:1084-93.
8. Tabone MD, Kalifa C, Rodary C, Raquin M, Valteau-Couanet D, Lemerle J. Osteosarcoma recurrences in pediatric patients previously treated with intensive chemotherapy. J Clin Oncol 1994;12:2614-20. (Pubitemid 24379647)
9. Ward WG, Mikaelian K, Dorey F, et al. Pulmonary metastases of stage IIB extremity osteosarcoma and subsequent pulmonary metastases. J Clin Oncol 1994;12:1849-58. (Pubitemid 24349387)
10. Dranoff G, Jaffee E, Lazenby A, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci U S A 1993;90:3539-43.
11. Kumar R, Yoneda J, Fidler IJ, Dong Z. GM-CSF-transduced B16 melanoma cells are highly susceptible to lysis by normal murine macrophages and poorly tumorigenic in immune-compromised mice. J Leukoc Biol 1999;65:102-8. (Pubitemid 29024923)
12. Anderson PM, Markovic SN, Sloan JA, et al. Aerosol granulocyte macrophage-colony stimulating factor: a low toxicity, lung-specific biological therapy in patients with lung metastases. Clin Cancer Res 1999;5:2316-23.
13. Armitage JO. Emerging applications of recombinant human granulocyte-macrophage colony-stimulating factor. Blood 1998;92:4491-508.
14. Di Carlo E, Forni G, Lollini P, Colombo MP, Modesti A, Musiani P. The intriguing role of polymorphonuclear neutrophils in antitumor reactions. Blood 2001;97:339-45.
15. Worth LL, Lafleur EA, Jia SF, Kleinerman ES. Fas expression inversely correlates with metastatic potential in osteosarcoma cells. Oncol Rep 2002;9:823-7.
16. Gordon N, Koshkina NV, Jia SF, et al. Corruption of the Fas pathway delays the pulmonary clearance of murine osteosarcoma cells, enhances their metastatic potential, and reduces the effect of aerosol gemcitabine. Clin Cancer Res 2007;13:4503-10.
17. Gordon N, Arndt CA, Hawkins DS, et al. Fas expression in lung metastasis from osteosarcoma patients. J Pediatr Hematol Oncol 2005;27:611-5.
18. Kalbfleisch J, Prentice R. The statistical analysis of failure time. New York: John Wiley and Sons; 2002.
19. Dunussi-Joannopoulos K, Dranoff G, Weinstein HJ, Ferrara JL, Bierer BE, Croop JM. Gene immunotherapy in murine acute myeloid leukemia: granulocyte-macrophage colony-stimulating factor tumor cell vaccines elicit more potent antitumor immunity compared with B7 family and other cytokine vaccines. Blood 1998;91:222-30. (Pubitemid 28018748)
20. Bernstein ZPBS, Hayes FA, Gould M, Jacob S, Tomasi B. A pilot study in the use of GM-CSF in human immunodeficiency virus (HIV) infected individuals. Blood 1997;90:133a.
21. Triozzi PL, Tucker F, Benzies T, Balcerzak SP. Antitumor and accessory immune activities of peripheral blood stem cells mobilized with granulocyte-macrophage colony-stimulating factor. Bone Marrow Transplant 1996;18:47-52. (Pubitemid 26289634)
22. Wiltschke C, Krainer M, Wagner A, Linkesch W, Zielinski CC. Influence of in vivo administration of GM-CSF and G-CSF on monocyte cytotoxicity. Exp Hematol 1995;23:402-6.
23. Baxevanis CN, Tsavaris NB, Papadhimitriou SI, et al. Granulocyte- macrophage colony-stimulating factor improves immunological parameters in patients with refractory solid tumours receiving second-line chemotherapy: correlation with clinical responses. Eur J Cancer 1997;33:1202-8.
24. Hart DN. Dendritic cells: unique leukocyte populations which control the primary immune response. Blood 1997;90:3245-87.
25. Koshkina NV, Kleinerman ES. Aerosol gemcitabine inhibits the growth of primary osteosarcoma and osteosarcoma lung metastases. Int J Cancer 2005;116:458-63.
26. Rao RD, Anderson PM, Arndt CA, Wettstein PJ, Markovic SN. Aerosolized granulocyte macrophage colony-stimulating factor (GM-CSF) therapy in metastatic cancer. Am J Clin Oncol 2003;26:493-8.
27. Markovic SN, Suman VJ, Nevala WK, et al. A dose-escalation study of aerosolized sargramostim in the treatment of metastatic melanoma: an NCCTG Study. Am J Clin Oncol 2008;31:573-9.
28. Rodriguez CO, Crabbs TA, Wilson DW, et al. Aerosol gemcitabine: preclinical safety and In vivo antitumor activity in osteosarcoma-bearing dogs. J Aerosol Med Pulm Drug Deliv 2009;22:1-10.
29. De Angulo G, Hernandez M, Morales-Arias J, et al. Early lymphocyte recovery as a prognostic indicator for high-risk Ewing sarcoma. J Pediatr Hematol Oncol 2007;29:48-52.
30. Sutphin R, Moore C. Prognostic signifance of early lymphocyte recovery in osteosarcoma (abstract). Pediatr Blood Cancer 2009;52:739, (poster 225).